Abstract: The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
May 24, 2022
Assignee:
Korea University Research and Business Foundation
Inventors:
Kyoung Heon Kim, Yong-Su Jin, Eun-Ju Yun, Dong-Hyun Kim, Sora Yu, Kyung-mun Cho, Na Jeong Park
Abstract: The subject invention pertains to methods and compositions for the treatment of erectile dysfunction (ED) (e.g., impotence) in a subject in need thereof utilizing one or more cannabinoid and one or more anti-ED drug.
Abstract: The present invention provides a bacterium and a method for the biological production of Heliotropin by the fermemtation of safrole. In one aspect of the present invention, a process for the conversion of safrole to Heliotropin is achieved by the use of a bacterial strain of Serratia liquefaciens ZMT-1 (CCTCC M 2016170). The production method comprises the steps of seeding the Serratia liquefaciens culture in the presence of oxygen for 24-36 hours, transforming the safrole substrate for 24-48 hours with 0.5-3 g/L substrate concentration, and reaching the Heliotropin concentration of 160-524 mg/L. The present invention reports, for the first time, on a method for producing the high concentration of Heliotropin by using the Serratia liquefaciens ZMT-1 strain or the enzyme extracted from the strain.
Abstract: The invention is directed to a culture medium for Haematococcus that contains combustion gases like carbon dioxide, carbon monoxide, and oxides of nitrogen or sulfur and which fixes the carbon, nitrogen or sulfur in these combustion gases into biomass and to methods providing superior biomass yields using this culture medium to culture select species of Haematococcus such as Haematococcus sp. KAU-01.
Type:
Grant
Filed:
April 12, 2021
Date of Patent:
May 10, 2022
Assignee:
King Abdulaziz University
Inventors:
Adnan Jaman Turki, Md. Abu Affan, Salim Marzoog Al-Harbi
Abstract: The present invention relates to the novel lactic acid bacteria Lactobacillus mucosae and Bifidobacterium longum, and specifically, to a composition comprising the novel lactic acid bacteria, the composition enabling the inhibition of the expression of the p16 protein, which is an aging factor, and the inhibition of inflammatory factors, thereby being useful in preventing and treating memory impairment, learning disabilities or mental disorders, and in preventing and treating inflammatory diseases.
Abstract: Disclosed herein is the novel use of use of a Bauhinia spp. extract, which may upregulate neprilysin, induce autophagy, protect neuron from amyloidopathy or tauopathy, and/or promote neurite outgrowth, thus the Bauhinia spp. extract of the present disclosure may be used as a dietary supplement for the prophylaxis or treatment of amyloid related neurodegenerative diseases so as to ameliorate or alleviate symptoms associated with the amyloid related neurodegenerative diseases.
Type:
Grant
Filed:
February 24, 2020
Date of Patent:
April 26, 2022
Assignees:
ACADEMIA SINICA, INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
Abstract: A therapeutic serum suitable for inclusion in a cosmetic preparation may be produced by stressing a co-culture including proliferative cells. The co-culture of cells may be obtained by growing first culture to less than one-hundred percent confluence on a surface. After a monolayer of first culture is established, a second culture may be seeded onto at least one cell free area on the surface, the resulting co-culture grown to less than one-hundred percent confluence. Additional cultures may then be seeded onto cell free areas of the surface and established until a monolayer having the desired population of cells is obtained. The monolayer is then stressed to obtain a serum by conditioning a collection medium. The obtained serum may be combined with a suitable cosmetic base to provide a cosmetic preparation.
Abstract: This invention relates to a composition for use in the treatment of major depressive disorder. In addition, this invention relates to a composition for use in the treatment and/or improvement of mood disturbances and for use in the treatment and/or improvement of the mood state.
Abstract: The present invention relates to a Petasites extract or pharmaceutical composition thereof for use in a method for treating viral infections.
Type:
Grant
Filed:
November 27, 2019
Date of Patent:
March 29, 2022
Assignee:
MAX ZELLER SOEHNE AG
Inventors:
Jurgen Drewe, Stephan Toff, Catherine Zahner
Abstract: The present disclosure provides compositions and methods for treating demyelinating conditions. More particularly, the present disclosure relates to compositions including DUOC-01 cell product and an anti-inflammatory agent; methods for preparing such compositions; and methods of using such compositions in combination or in conjunction with each other for treatment of treating demyelinating conditions.
Type:
Grant
Filed:
July 12, 2019
Date of Patent:
March 22, 2022
Assignee:
Duke University
Inventors:
Joanne Kurtzberg, Andrew E. Balber, Arjun Saha, Pamela Noldner, Paula Scotland
Abstract: The present invention discloses an application of Bacteroides cellulosilyticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases, such as atherosclerosis related diseases, cardiovascular diseases and obesity.
Abstract: Spent stillage remaining after the fermentation of a feedstock for ethanol production may be processed to recover, use, and/or recycle the constituent components of the stillage. Stillage may be mixed, heated, and held at a desired temperature for a period of time. The stillage may then be cooled and treated with an enzyme. The enzymatically treated stillage may be emulsified with oil and water, and then permitted to settle into discrete layers. Individual layers may then be processed.
Abstract: Disclosed are nutritional compositions including 2?-fucosyllactose (2?-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.
Abstract: The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.
Abstract: The present invention provides a method for preparing salidroside. The present invention uses ?-glucoside and CoFe2O4 particles to form a cross-linked aggregate capable of effectively catalyzing the reaction of ?-D-glucose and tyrosol, thereby increasing the yield of the salidroside. The steps of the preparation method of the present invention are simple and short, and the method is easy to operate and readily applicable to industrial production.
Abstract: The subject invention pertains to methods and compositions for the treatment of erectile dysfunction (ED) (e.g., impotence) in a subject in need thereof utilizing one or more cannabinoid and one or more anti-ED drug.
Abstract: Disclosed herein are antimicrobial compositions that are substantially odorless. The antimicrobial compositions can comprise, for example, a first essential oil and a second essential oil, wherein the composition is substantially odorless. In some examples, the composition can further comprise a third essential oil. The compositions described herein can, for example, reduce the population of microbes, such as Staphylococcus aureus or Escherichia coli, by 5 log or more. Also disclosed herein are beverages and food products including the compositions disclosed herein. Also disclosed herein is milk including the compositions disclosed herein. Also disclosed herein are methods for treating or preventing a microbial infection in a subject, the methods comprising administering to the subject an effective amount of any of the compositions disclosed herein. Also disclosed herein are methods for combating bovine mastitis, the methods comprising applying any of the compositions disclosed herein to cow udders.
Type:
Grant
Filed:
January 5, 2018
Date of Patent:
February 15, 2022
Assignee:
CROWPIERCE TECHNOLOGIES, LLC
Inventors:
George Pierce, Sidney Crow, Amber Keller
Abstract: A composition and method for ameliorating drug-seeking behavior in drug addicts who have stopped using the addicted-to drug and who have reestablished non-addict physiological chemical balance.
Abstract: Disclosed herein are compositions and methods for acutely raising nitric oxide levels in a subject. In one example, the composition can include, an effective amount of a NOS dependent source of nitric oxide; an effective amount of a NOS independent source of nitric oxide; and an effective amount of a myeloperoxidase inhibitor; wherein the composition acutely raises nitric oxide levels in a subject above a level provided by the available sources of nitric oxide in the subject prior to administration of the composition. Further presented is a method of treating a subject for a condition or disorder that is response to nitric oxide therapy, including: acutely raising nitric oxide levels in a subject by simultaneously increasing biosynthesis of nitric oxide, increasing nitrate/nitrite levels, and inhibiting myeloperoxidase activity.
Type:
Grant
Filed:
August 28, 2016
Date of Patent:
February 8, 2022
Assignee:
Nature's Sunshine Products, Inc.
Inventors:
Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Mohan Kaadige, Wei Gao
Abstract: Thin film devices, e.g., multilayer thin film devices, that encapsulate cells for transplantation into a subject are provided. Also provided are methods of using and methods of preparing the subject devices. The thin film devices include a first porous polymer layer and a second porous polymer layer that define a lumen therebetween and encapsulate a population of cells within the lumen. The thin film devices can promote vascularization into the lumen of the device via the pores in the first polymer layer and/or second polymer layer; limit foreign body response to the device; limit ingress of cells, immunoglobulins, and cytokines into the lumen via the first and the second polymer layers; and release from the first polymer layer and/or the second polymer layer molecules secreted by the population of cells.
Type:
Grant
Filed:
October 23, 2019
Date of Patent:
February 1, 2022
Assignee:
The Regents of the University of California
Inventors:
Tejal Ashwin Desai, Crystal Nyitray, Ryan Chang